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Abstract
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Humanized mice (hu-mice) that feature a functional human immune system have fundamentally
changed the study of human pathogens and disease. They can be used to model diseases that are
otherwise difficult or impossible to study in humans or other animal models. The gut microbiome
can have a profound impact on human health and disease. However, the murine gut microbiome is
very different than the one found in humans. There is a need for improved pre-clinical hu-mice
models that have an engrafted human gut microbiome. Therefore, we created double hu-mice that
feature both a human immune system and stable human-like gut microbiome. NOD.CgPrkdcscidIl2rgtm1Wjl/SzJ (NSG) mice are one of the best animals for humanization due to their
high level of immunodeficiency. However, germ-free NSG mice, and various other important
germ-free mice models are not currently commercially available. Further, many research settings
do not have access to gnotobiotic facilities, and working under gnotobiotic conditions can often be
expensive and time consuming. Importantly, germ-free mice have several immune deficiencies that
exist even after the engraftment of microbes. Therefore, we developed a protocol that does not
require germ-free animals or gnotobiotic facilities. To generate double hu-mice, NSG mice were
treated with radiation prior to surgery to create bone-marrow, liver, thymus-humanized (hu-BLT)
mice. The mice were then treated with broad spectrum antibiotics to deplete the pre-existing
murine gut microbiome. After antibiotic treatment, the mice were given fecal transplants with
healthy human donor samples via oral gavage. Double hu-BLT mice had unique 16S rRNA gene
profiles based on the individual human donor sample that was transplanted. Importantly, the
transplanted human-like microbiome was stable in the double hu-BLT mice for the duration of the
study up to 14.5 weeks post-transplant.
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Humanized mice (hu-mice) have transformed the study of many aspects of human health and
disease including hematopoiesis, immunity, cancer, autoimmune disease, and infectious
disease1,2,3,4,5,6,7,8,9. These hu-mice have the distinct advantage over other mouse models in
that they have a functional human immune system and can be infected with human specific
pathogens. Nevertheless, the importance of the gut microbiome has been demonstrated by its
role in many human diseases such as obesity, metabolic syndrome, inflammatory diseases,
and cancer10,11,12,13. The mucosal immune system and gut microbiome are reciprocally
regulated to maintain gut and systemic homeostasis. The immune system is shaped by
antigens presented by the gut microbiome and reciprocally the immune system plays an
important regulatory role in promoting commensal gut bacteria and eliminating
pathogens14,15,16. However, the gut microbiome of hu-mice has not been well characterized
and the murine gut microbiome differs substantially in composition and function from
humans17. This is due to evolutionary, physiological, and anatomical differences between
the murine and human gut as well as other important factors such as diet, which may
influence the experimental results of hu-mice disease models18. Therefore, beyond
classification of murine gut microbiome of hu-mice, an animal model featuring both a
human immune system and human gut microbiome is needed to study the complex
interactions of human disease in vivo. The study of human diseases directly in human
subjects is often impractical or unethical. Many animal models cannot be used to study
human pathogens like human immunodeficiency virus type 1 (HIV-1). Non-human primate
models are genetically outbred, very expensive, and are not susceptible to many human
pathogens. Mice that have been derived as germ free (GF) and reconstituted with human-like
gut microbiomes have been widely used to study human health and disease19,20. However,
these animals do not have a human immune system and working with GF animals requires
specialized facilities, procedures, and expertise. Therefore, there is a need for improved preclinical models to study the complex relationship of the gut microbiome and the human
immune system. Many strains of mice, such as NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG), are
not commercially available as GF. GF animals also may suffer from long-lasting immune
deficiencies that are not completely reversed by the engraftment of microbes21. Therefore,
we created a double hu-mice featuring both a functional human immune system and stable
humanlike gut microbiome under specific pathogen free (SPF) conditions. To generate
double hu-mice, surgery was performed on NSG mice to create bone-marrow, liver, thymus
humanized mice (hu-BLT). The hu-BLT mice were then treated with broad spectrum
antibiotics and then given fecal transplants with a healthy human donor sample. We
characterized the bacterial gut microbiome of 173 fecal samples from 45 double hu-BLT
mice and 4 human fecal donor samples. Double hu-BLT mice have unique 16S rRNA gene
profiles based on the individual human donor sample that is transplanted. Importantly, the
transplanted human-like microbiome was stable in the mice for the duration of the study up
to 14.5 weeks post-transplant. In addition, the predicted metagenomes showed that double
hu-BLT mice have different predicted functional capacity than hu-mice that is more similar
to the human donor samples.
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All methods described here were conducted in accordance with Institutional Animal Care
and Research Committee (IACUC)-approved protocols at the University of NebraskaLincoln (UNL). The IACUC at UNL has approved two protocols related to generating and
using hu-BLT mice,including double hu-mice. Additionally, the Scientific Research
Oversight Committee (SROC) at UNL has also approved the use of human embryonic stem
cells and fetal tissues, which are procured from the Advanced Bioscience Resources for
humanized mice studies (SROC#2016–1-002).
1. Mice housing and maintenance—1.1. Purchase 6–8-week old NSG mice
(NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ).

Author Manuscript

1.2. House the mice under SPF conditions with air exchange, prefilters, and HEPA filters
(0.22 μm) in a room with controlled temperature, humidity, and pressure.
1.2.1. House and maintain the mice in autoclaved individual microisolator cages in a rack
system capable of managing air exchange with prefilters and HEPA filters (0.22 μm).
1.3. Perform all procedures and manipulations of the mice in a Class II Type A2 biological
safety fume hood that has been pre-treated with 70% ethanol. Before working in the animal
room, shower and change into clean scrubs, tyvek suit, boot covers, hair cap, face mask, and
gloves. Wear a surgery gown over the tyvek suit during surgical procedures.
NOTE: Ultraviolet (UV) light decontamination is also preferred prior to procedures.
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1.3.1. Autoclave all instruments and reagents if possible and then disinfect prior to
transferring to the fume hood.
1.3.2. During procedures, remove the animals’ individually-ventilated cages from the rack
and disinfect prior to transferring to the fume hood.
1.4. Feed the mice an irradiated diet and provide autoclaved water. Provide irradiated food
ab libitum and supplement with additional irradiated food as needed. Change autoclaved
water weekly or as needed.
NOTE: Autoclaved acidified water can also be used. The irradiated diet provided had a
shelf-life of 6 months after manufacture.

Author Manuscript

2. Generation of humanized BLT mice—NOTE: Generation of hu-BLT mice has
been described previously22,23,24.
2.1. On the day of surgery, give the mice whole-body irradiation at a dose of 12 cGy/g of
body weight.
2.2. Prepare the mice for surgery.
2.1. Give each irradiated mouse a mixture of Ketamine at the working concentration of 100
mg/kg and Xylazine at the concentration of 12 mg/kg, which ranged from 130– 170 μL per
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mouse based on body weight by intraperitoneal (IP) injection for anesthesia. To prepare 3 ml
of the Ketamine and Xylazine mixture, add 0.27 mL of Ketamine at the stock concentration
of 100 mg/mL and 0.03 mL of Xylazine at the concentration of 100 mg/mL to 2.7 mL of
sterile saline and mix well. Disinfect the skin with 70% isopropanol prior to injection.
2.2. Give each irradiated mouse Buprenorphine 1 mg/kg of body weight (half-live 72 h, SRLAB) by subcutaneous injection for long lasting pain management.
2.3. Give each irradiated mouse 100 μL (858 μg) of Cefazolin by IP injection for
preoperative antibiotic prophylaxis.
2.4. Shave the hair of the mice using electric hair clippers around the left lateral and medial
side of the mouse at the later surgical site used to expose the left kidney.
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2.5. Verify proper level of anesthesia by pedal reflex (firm toe pinch).
2.6. Give isoflurane gas at 3–5% if additional anesthesia is needed at any point during
surgery.
2.7. Apply ophthalmic ointment to both eyes to prevent corneal desiccation. Apply ear tag if
needed.
3. Perform surgery to implant the liver and thymus tissues into the left kidney capsule.
3.1. Disinfect the skin at the surgical site by applying iodine scrub starting from the Center
of the surgical site and moving towards the outside in a circular manner. Repeat this process
with 70% isopropanol and a third time with iodine.

Author Manuscript

3.2. Using forceps, first load one human fetal liver tissue fragment into a trocar. Then using
forceps, load one human fetal thymus tissue fragment into the trocar. Then using forceps,
load another human fetal liver tissue fragment into the trocar. Tissues should be cut to 1–1.6
mm3 to fit the inner dimensions of the trocar.
3.3. Use forceps to lift the skin and use scissors to make a small cut longitudinally. Extend
the cut to 1.5–2 cm in the left side of the mouse.
3.4. Use forceps to lift the muscle layer and use scissors to make a small cut longitudinally.
Extend the cut as needed to expose the kidney.

Author Manuscript

3.5. Expose the kidney by gently grasping the fatty tissue surrounding the kidney. Do not
directly touch the kidney parenchyma.
3.6. Make a 1–2 mm incision at the posterior end of the kidney capsule using a scalpel.
3.7. Slowly insert the preloaded trocar through the incision parallel to the long axis of the
kidney and release the tissues between the kidney capsule and kidney.
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3.8. Carefully return the kidney and bowel to their normal position. Use absorbable 5/0 P-3
(P-13) sutures with 13mm 3/8 circle needle to close the muscle layer and Surgical staples to
close the skin.
4. After surgery, put the mouse into a clean autoclaved microisolator cage for recovery.
4.1. To minimize heat loss during post-surgical recovery, put the cage containing the mice on
a heating pad that is connected to a water pump that warms and circulates the water.
4.2. Monitor the mice until they have regained sufficient consciousness to maintain sternal
recumbency.
5. Within 6 h of surgery completion, via the tail-vein, inject CD34+ hematopoietic stem cells
isolated from human fetal liver tissue.

Author Manuscript

5.1. Warm up the mice with a heat-lamp. Disinfect the tail with 70% isopropanol and then
inject 1.5 to 5 × 105 stem cells/200 μL into the tail vein.
5.2. Stop any bleeding from the injection and return mice to the microisolator cage and the
microisolator cage to the cage rack.
NOTE: Post-surgery mice are typically housed together, five per microisolator cage, during
and after recovery. However, mice are only housed together if they all received surgery on
the same day.
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6. Check the mice daily. Carefully monitor the surgical staples and replace them as needed.
Closely monitor the mice for any sign of infection or discomfort. Supply autoclaved food on
the floor of the microisolator cage for a few days post surgery.
7. Remove the surgical staples 7–10 days after surgery. Give isoflurane gas at 3–5% to
anesthetize the mice. Carefully remove the staples and then apply antibiotic and painrelieving ointment onto the site.
8. Allow 9–12 weeks for reconstitution of human immune cells, then collect peripheral
blood from the medial saphenous vein from each of the humanized mice.
8.1. Restrain conscious mice using an appropriately sized plastic cone restraint with an
opening near the head of the mouse for breathing and an opening near the back of the mouse
to isolate one leg. Put the mice into the restraint cone head first and then gently pull one leg
through the leg opening.

Author Manuscript

8.2. Spray the medial side of the isolated leg with 70% isopropanol, then spread antibiotic
and pain-relieving ointment onto the same site.
NOTE: The ointment helps to reveal the location of the vein without the need for hair
removal and also assists in blood droplet formation.
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8.3. Using a 25-gauge needle at a 90° angle, puncture the vein and collect 50–100 μL of
blood using an EDTA coated blood collection tube Stop the bleeding by applying pressure to
the site with sterile gauze. Once the bleeding has stopped, return the mice to their cage.
NOTE: The maximum blood volumes collected are typically 50 μL per week or 100 μL
every two weeks.
8.4. Use the collected peripheral blood to test the level of human immune cell reconstitution
using flow cytometry with antibodies for hCD45, mCD45, hCD3, hCD4, hCD8, hCD19.
3. Antibiotic treatment—1. Prior to antibiotic treatment, collect pre-treatment fecal
samples. Move the mice to a new autoclaved microisolator cage.
2. Prepare a fresh cocktail of broad-spectrum antibiotics daily.
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2.1. Prepare 250 mL of water containing freshly prepared Metronidazole (1 g/L), Neomycin
(1 g/L), Vancomycin (0.5 g/L), and Ampicillin (1 g/L) for each microisolator cage of mice.
NOTE: Use autoclaved or sterile water for the antibiotic supplemented drinking water.
2.2. Add 9.2 g of grape sugar sweetened drink mix to 250 mL of antibiotic supplemented
water.
NOTE: The use of grape sugar sweetened drink mix masks the bitter taste of the antibiotics
and helps prevent dehydration in the mice.
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2.3. Change the antibiotic and grape sugar sweetened drink mix supplemented water and
place the mice in a new autoclaved cage daily.
NOTE: Mice are coprophagic and changing the cages daily prevents the mice from reinoculating themselves with gut bacteria.
2.4. For maximal engraftment of the human-like gut microbiome, provide antibiotics for 14
days. During antibiotic treatment, monitor the mice for weight loss and dehydration. Weight
loss is expected during the first 3–4 days and plateaus after that for the duration of the
treatment. If dehydration occurs, give the mice saline or Ringers Solution via intraperitoneal
injection.
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NOTE: Other gut microbiome humanization protocols call for oral gavage of antibiotics.
While effective at depleting the murine gut bacteria, we found that the less invasive method
of adding antibiotics to the drinking water put less stress on our humanized mice and led to
better outcomes.
4.

Donor samples and fecal transplant—1. Prepare human donor fecal samples.

1.1. Use properly prepared sources of fecal microbiota transplant (FMT) material for fecal
transplant into the humanized mice.
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1.2. Thaw FMT preparations and aliquot them under anaerobic conditions in an anaerobic
chamber.
1.3. If desired, at this step mix equal parts of the fecal samples together to create an unbiased
“human” sample.
1.4. Keep freezing and thawing of the FMT material to a minimum, if aliquoting or mixing
of samples is not needed, only thaw immediately before the procedure.
2. Human fecal transplant
2.1. After completion of 14 days antibiotic treatment, change the drinking water to
autoclaved water and move the mice into a new autoclaved cage. Stop daily cage changes
and implement a once every 1–2 weeks cage changing schedule.

Author Manuscript

2.2. Give two fecal transplants at 24 and 48 h post cessation of antibiotics.
3. 24 h after antibiotics treatment, thaw the needed amount of FMT material, give each
mouse 200 μL of FMT material via oral gavage. Repeat procedure again at 48 h post
antibiotics.
4. Spread any remaining or leftover thawed FMT material on the fur of the humanized mice
or onto the cage bedding.
5. Fresh fecal sample collection—1. Autoclave individual paper bags prior to
transferring to the fume hood.
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2. In the fume hood, put one mouse into each individual paper bag and allow the mouse to
defecate.
3. Using sterile forceps, collect the fecal sample into 1.5 mL plastic tubes and freeze at
−80 °C. Return the mice to microisolator cages.
NOTE: This method of collecting fecal samples allows for fresh fecal sample collection
from individual mice without any stress inducing manipulations.

Representative Results
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Figure 1 shows an outline of the methods used to create double hu-BLT mice and briefly
describes the process of adding a functional human immune system and stable human-like
gut microbiome to the NSG mice. Figure 2 shows an example of flow cytometry analysis of
peripheral blood from a humanized BLT-mouse 10 weeks post-surgery. Figure 3 shows the
relative abundance of the human fecal donor samples used to transfer a gut microbiome to
create double hu-mice. Figure 4 shows the phenotypic changes induced by antibiotic
treatment to the spleen and cecum, similar to what is observed in germ-free animals. Figure
5 shows a principal component analysis (PCA) plot of the 16S rRNA sequencing data
revealing double hu-mice have human-like gut microbiomes that are unique to the human
donor sample.
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Discussion
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The protocol described here is for the creation of double hu-BLT mice that feature both a
functional human immune system and a stable humanlike gut microbiome. This protocol can
be adapted to other humanized or non-humanized mice models without the need for GF
animals and gnotobiotic facilities. While the methods described here are relatively simple,
there are several critical details that are important for the successful creation of double huBLT mice. NSG mice are extremely immunodeficient and preventing infections is key to
long-term survival of the mice. We took following measures to prevent infection. First,
animals were housed in individual microisolator cages with HEPA filters (0.22 μm) in a rack
system with air exchange rate management in a dedicated suite. The air handler for the rack
contained pre-filters along with HEPA filtered (0.22 μm) supply and exhaust air, as well as
real-time on-line monitoring of cage exhaust air temperature and relative humidity. Second,
everyone who entered the animal room had to shower and wear clean scrubs and shoes as
well as put on gloves, disposable tyvek suit, booties, hair bonnet, and face mask. Third, all
procedures, including cage changes and addition of food and water, were performed within a
Class II Type A2 biological safety fume hood that was pre-sterilized with 70% ethanol and
UV light. Fourth, aseptic surgical technique was used during survival surgery, which
included the surgeon and assistants wearing an additional layer of protection including a
surgery gown and gloves. Surgery was conducted in the disinfected fume hood, using only
sterile instruments, gauzes, and wound closure materials, while maintaining the sterility of
gloves and instruments throughout the surgery. Finally, to prevent infection and ensure the
stability of the engrafted human-like gut microbiome, all food and water given to the mice
was sterile. All food should be irradiated and all water should be autoclaved. To minimize
pain and distress, we administered long-acting buprenorphine subcutaneously to mice before
surgery. The combination of Ketamine and Xylazine for mouse surgical anesthesia is very
reliable and can last about for 30 min. If that is not long-enough, we give isoflurane gas to
further anesthetize the mice. It is also very important to maintain mouse body temperature
post-surgery. We put the cage on the heated warming pad until the hematopoietic stem cell
injection via the tail vein. At that time, the mice are recovered from anesthesia and returned
to rack.
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To deplete the murine gut microbiome and prepare for human fecal transplant, it is important
to always use freshly prepared antibiotics and to change antibiotic supplemented water and
cages daily. This will use many microisolator cages throughout the 14-day antibiotic
treatment, but it ensures the mice are not being re-inoculated through coprophagia. During
antibiotic treatment, it is also critical to monitor the body weight and health of the mice.
After fecal transplant, the mice quickly regain any lost weight. It is important to minimize
any freeze-thaw cycles for the fecal transplant material and to make sure to use an anaerobic
chamber if aliquoting samples is needed. While creating double hu-BLT mice it is important
to minimize handling and stress induced on the mice. This helps to prevent infection and
improves long-term survival.
We initially tried to pre-treat mice with anti-fungal amphotericin B but found the mice did
not tolerate the treatment very well and it is no longer used. We also experimented with
different durations of antibiotic treatment. We found that while a majority of murine gut
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bacteria appear to be depleted after 7 days of antibiotics, the level of donor engraftment is
much higher after 14 days of treatment. We also tried administering antibiotics through
twice-daily oral gavage. However, we found that this method was too invasive for our humice. We switched to a single daily gavage schedule but the mice still appeared to be
stressed and unhealthy. We found that providing antibiotics in the drinking water was the
best method. It reduced the amount handling and stress to the mice while still adequately
reducing the murine gut bacteria. We provided grape sugar sweetened drink mix in the
drinking water to ensure the mice received an adequate dosage of antibiotic and to prevent
dehydration. The mice do experience a reduction in body weight during the first 3–4 days of
antibiotic treatment, but providing extra fluids via intraperitoneal injection does not increase
body weight. After fecal transplant, the mice quickly regain the lost weight.
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While this method is able to reproducibly generate double hu-BLT mice, there are some
limitations to the model. The first thing to consider is hu-mice have less organized lymphoid
structure, including the germinal center, leading to reduced antibody class switching and
limited affinity maturation. However, NSG hu-BLT mice have systemic immune
reconstitution and translatable T cell responses and can be used to model many human
diseases. Another issue is the potential development of graft-versus-host disease (GVHD) in
some hu-mice after several months of excessive human immune reconstitution. We and
others have observed GVHD manifestations such as blepharitis, alopecia, weight loss, and
malocclusion that must be carefully monitored25.
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There are several documented regimens for depleting gut bacteria in mice with
antibiotics26,27,28,29,30,31. We chose our cocktail of antibiotics due to their known capacity to
target a broad range of bacteria in the gut and because we found several examples of
successful bacterial depletion in the literature. Many published cases use a far less rigorous
course of antibiotics but in our study, we found that 14 days is needed for optimal
engraftment of a human-like gut microbiome. While we initially tried a protocol based on
Hintze et al., we found that oral gavage was too invasive and that anti-fungal treatment was
detrimental to mice26. We believe that NSG hu-BLT mice are unique and less invasive
procedures are preferred compared to other more robust mice. We did not use GF animals in
our study. The use of GF mice to study the effects of the gut microbiome have been welldocumented, however, these animals do not have a human immune system19,32. Further, we
admit that working with a GF NSG hu-BLT mice model would create interesting
opportunities for research. For one, studying human immune cell reconstitution and the
pathogenesis of human specific pathogens like HIV-1 without the presence of the gut
microbiome could provide interesting results. Further, GF models may allow for a more
complete reconstitution of a human-like gut microbiome following fecal transplant.
However, GF mice have longlasting immune deficiencies, even after gut microbiome
reconstitution21. Our model has the advantage of using SPF housing conditions, which are
widely available and less expensive compared to GF facilities. Our model also has the
advantage of not perturbing the normal procedures of surgically generating hu-BLT mice
because there is no need for a completely GF environment.
We believe that this double hu-BLT mouse model is unique in that it not only can be used to
study human immune function and human diseases, but also determine the impact of the gut
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microbiome on disease pathogenesis and treatment in vivo. With this protocol, we can
reproducibly create double hu-BLT mice with human donor specific gut microbiome
profiles. Therefore, we believe that using double hu-BLT mice will be beneficial to future
personalized medicine applications designed to test the impact of the gut microbiome on
treatments for various human diseases like HIV-1 and cancer. In summary, our double huBLT mice model is an important and novel pre-clinical model that features both a functional
human immune system and a stable human-like gut microbiome to study human health and
disease.
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Figure 1: Creating double humanized BLT-mice.
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Creating double hu-BLT mice is a two-step process. The first step is to engraft the human
immune system to the NSG mice. On the day of surgery, NSG mice are given irradiation to
create a niche for stem cells. The mice are then implanted with human fetal liver and thymus
tissues and injected with human hematopoietic stem cells. Human immune cell
reconstitution is checked around 10 weeks post-surgery. The second step is to engraft the
human gut microbiome. Mice are treated with antibiotics to reduce the pre-existing murine
gut bacteria. Mice are then given fecal transplants to provide the human gut microbiome.
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Figure 2: Testing human immune cell reconstitution in double humanized BLT-mice.

An example of flow cytometry analysis of a humanized BLT-mouse peripheral blood 10
weeks post-surgery. The figure shows the gating strategy used to identify the lymphocyte
population, mCD45-hCD45+ cells, CD19+ B cells, CD3+ T cells, CD4+ T cells, and CD8+
T cells.
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Figure 3: Human donor fecal sample profiles.
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Relative abundance of the 3 human donor and mixed (all donors) samples shown at the
family level.
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Figure 4: Antibiotic treated mice resemble germ-free phenotypes.
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Hu-mice were sacrificed after 9 days of antibiotic treatment (Antibiotics) or no antibiotic
treatment (Control). After antibiotic treatment, the phenotype of the humanized mice begins
to resemble those seen in germ-free animals. As a result of antibiotic treatment there is a
reduction in the size of the spleen (left) and the cecum is enlarged (right).
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Figure 5: Double humanized BLT-mice feature fecal donor specific gut microbiomes.

PCA plot of 16S rRNA sequencing data show after human fecal transplant the double huBLT mice feature gut microbiomes that are unique to the individual human fecal donor.

Author Manuscript
Author Manuscript
J Vis Exp. Author manuscript; available in PMC 2020 February 10.

